Spero Therapeutics, Inc. announced that effective as of July 2, 2022, Cristina Larkin will separate from the company as its Chief Operating Officer pursuant to the Restructuring. In connection with Ms. Larkin's separation, the Company and Ms. Larkin entered into a separation agreement (the Larkin Separation Agreement), dated as of May 3, 2022, and Ms. Larkin received notice pursuant to the Worker Adjustment and Retraining Notification Act of 1988 (the WARN Act). Effective as of the Effective Date, David Melnick, M.D. will separate from the Company as its Chief Medical Officer pursuant to the Restructuring.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.405 USD | -3.10% | -1.06% | -4.42% |
05-15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
05-15 | Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.42% | 78.28M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. Announces Executive Changes